Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with improved survival in some cancers, but evidence for ovarian cancer is limited. METHODS: Pooling individual-level data from 12 Ovarian Cancer Association Consortium studies, we evaluated the association between self-reported, pre-diagnosis use of common analgesics and overall/progression-free/disease-specific survival among 7694 women with invasive epithelial ovarian cancer (4273 deaths). RESULTS: Regular analgesic use (at least once per week) was not associated with overall survival (pooled hazard ratios, pHRs (95% confidence intervals): aspirin 0.96 (0.88-1.04); non-aspirin NSAIDs 0.97 (0.89-1.05); acetaminophen 1.01 (0.93-1.10)), nor with progression-free/disease-specific survival. There was however a survival advantage for users of any NSAIDs in studies clearly defining non-use as less than once per week (pHR=0.89 (0.82-0.98)). CONCLUSIONS: Although this study did not show a clear association between analgesic use and ovarian cancer survival, further investigation with clearer definitions of use and information about post-diagnosis use is warranted.
Dixon, SC; Nagle, CM; Wentzensen, N; Trabert, B; Beeghly-Fadiel, A; Schildkraut, JM; Moysich, KB; deFazio, A; Australian Ovarian Cancer Study Group, ; Risch, HA; Rossing, MA; Doherty, JA; Wicklund, KG; Goodman, MT; Modugno, F; Ness, RB; Edwards, RP; Jensen, A; Kjær, SK; Høgdall, E; Berchuck, A; Cramer, DW; Terry, KL; Poole, EM; Bandera, EV; Paddock, LE; Anton-Culver, H; Ziogas, A; Menon, U; Gayther, SA; Ramus, SJ; Gentry-Maharaj, A; Pearce, CL; Wu, AH; Pike, MC; Webb, PM
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)